

PRESS RELEASE

May 2, 2005



ICON plc
South County Business Park
Leopardstown
Dublin 18
Ireland

Tel +353 1 291 2000
Fax + 353 1 291 2200
e-mail info@iconirl.com
Web www.iconclinical.com

ICON named “Top CRO” for quality and execution in pharma industry survey May 2nd, 2005

Philadelphia, PA, May 2, 2005

ICON Clinical Research was cited as the “favorite CRO” in a recent survey of 23 pharmaceutical and biotech companies. The survey, which was conducted in late 2004 by investment banking firm William Blair & Company and research firm PharmaMediation, Inc. measured industry attitudes on CRO quality, execution and service. In its summary statement, the survey noted that “ICON was mentioned most frequently as a favorite CRO vendor; this matched our perception that this company is one of the best in terms of quality.”

More than 50 CROs were mentioned by respondents in the survey, with ICON, PAREXEL, PPD, Quintiles and Covance cited most frequently as the best “full-service CRO vendors.” ICON was also listed in the top three “niche CROs” for its IVRS service reflecting the company’s ability to offer broad services to meet clients’ specialized requirements. ICON also received the most mentions for “CRO showing the most improvement over the past year.”

“ICON’s strong showing in the Blair/PharmaMediation survey is very gratifying,” said Peter Gray, ICON’s CEO. “It is a validation of our company’s dedication to quality and the exceptional effort of ICON employees around the world.”

ICON is a full-service contract research organization providing a comprehensive range of clinical services in Phase I-IV clinical research studies to the pharmaceutical, biotechnology and device industries. With more than 37 offices in 23 countries and over 2,600 employees worldwide, ICON has the infrastructure necessary to support the many global mega trials it is currently conducting, but remains flexible enough to provide an individual, highly personalized service for locally managed projects. For more information about ICON Clinical Research, visit www.iconclinical.com

For more information about the Blair/PharmaMediation survey contact
RMailResponse@williamblair.com